Recent Updates
Recently added Catalysts
RDY

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Key Takeaway: Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Exchan

Full Press Release Details

Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN: L85195TG1984PLC004507
Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com
Corporate Relationship Department National Stock Exchange of India Ltd.
BSE Limited "Exchange Plaza"
Dalal Street, Fort Bandra-Kurla Complex, Bandra (East),
Mumbai - 400 001 Mumbai - 400 051
Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039 26598238
Scrip Code: 500124 Scrip Code: DRREDDY-EQ
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 40th Annual Global Healthcare Conference"
This is for your information.
/s/ Sandeep Poddar
Sandeep Poddar
Company Secretary
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
CONTACT
DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40- 49002121)
Laboratories Limited to present at the
Sachs 40th Annual Global Healthcare Conference
Hyderabad, India and Princeton, NJ, USA. June 12th,
2019 - Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting
at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12th, 2019, in California.
Marc Kikuchi, CEO, North America Generics will present at Fireside
Chat session at 2:00 p.m. PST [2:30 a.m. IST on June 13th, 2019].
Presentation material will be available on the Company's
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information
Last updated: Jun 12, 2019